Djurhuus Sissal Sigmundsdòttir, Brasso Klaus, Berg Kasper Drimer, Iversen Peter, Røder Martin Andreas
Copenhagen Prostate Cancer Center, Rigshospitalet, Tagensvej 20, 2200 København N.
Ugeskr Laeger. 2015 May 11;177(20).
Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.
去势抵抗性前列腺癌（CRPC）被定义为尽管血清睾酮水平处于去势状态，但肿瘤仍进展。在过去十年中，包括化疗和新型内分泌药物在内的多种新疗法已被批准用于CRPC治疗。CRPC对新型有效药物的持续需求促使了一种用于CRPC治疗的新型治疗方法的发展。治疗性疫苗可激活免疫系统以杀死前列腺癌细胞。本综述描述了CRPC疫苗最近的关键2期和3期试验，并讨论了其对未来CRPC管理的影响。
